{"denoms":[{"counts":[{"groupId":"BG000","value":"52"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.\n\nTRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure.\n\nclofarabine: Given IV\n\nmelphalan: Given IV\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\ntacrolimus: Given IV or PO\n\nsirolimus: Given PO\n\nPharmacological Study: Correlative studies","id":"BG000","title":"Treatment (Clofarabine, Melphalan, Transplant)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"71","value":"62"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"42"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}